Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
Abstract Multiple myeloma (MM) remains a difficult-to-cure hematologic malignancy. Although B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has substantially deepened clinical responses in patients with relapsed/refractory MM, its broader clinical application remains constrain...